Skip to main content
53°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
June 24, 2024
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
May 20, 2024
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
April 09, 2024
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
April 04, 2024
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 25, 2024
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 05, 2024
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
January 29, 2024
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
January 25, 2024
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
January 09, 2024
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics Announces Reverse Stock Split
January 09, 2024
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
December 08, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
November 28, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting
November 15, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference
November 06, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia
October 24, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors
September 11, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
August 30, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings
June 08, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
June 07, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
May 31, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
May 26, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting
May 25, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference
May 08, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual Meeting
April 26, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer
April 11, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
March 28, 2023
From
eFFECTOR Therapeutics, Inc.
Via
GlobeNewswire
Tickers
EFTR
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.